The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Prostate-specific membrane antigen expression as a predictor of prostate cancer progression
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer
Bill-Axelson, A., Holmberg, L., Ruutu, M., Garmo, H., Stark, J. R., Busch, C., Nordling, S., Häggman, M., Andersson, S.-O., Bratell, S., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011967 · Cited by 1,900
(1997) · PubMed · Cited by 1,541
Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer
Bill-Axelson, A., Holmberg, L., Ruutu, M., Häggman, M., Andersson, S.-O., Bratell, S., Spångberg, A., Busch, C., Nordling, S., Garmo, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043739 · Cited by 1,111
Classification of prostatic carcinomas.
Gleason, D. F. (1966) · PubMed · Cited by 1,110
Histologic grading of prostate cancer: A perspective
Gleason, D. F. (1992) · Human Pathology · doi:10.1016/0046-8177(92)90108-f · Cited by 1,034
Bostwick, D. G., Pacelli, A., Blute, M., Roche, P., & Murphy, G. P. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980601)82:11<2256::aid-cncr22>3.0.co;2-s · Cited by 698
Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy
Wright, G. L., Mayer Grob, B., Haley, C., Grossman, K., Newhall, K., Petrylak, D., Troyer, J., Konchuba, A., Schellhammer, P. F., & Moriarty, R. (1996) · Urology · doi:10.1016/s0090-4295(96)00184-7 · Cited by 635
Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases
Shah, R. B., Mehra, R., Chinnaiyan, A. M., Shen, R., Ghosh, D., Zhou, M., MacVicar, G. R., Varambally, S., Harwood, J., Bismar, T. A., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2442 · Cited by 617
Self-citationSweat, S. D., Pacelli, A., Murphy, G. P., & Bostwick, D. G. (1998) · Urology · doi:10.1016/s0090-4295(98)00278-7 · Cited by 607
Expression of the prostate-specific membrane antigen.
Israeli, R., Powell, C. T., Corr, J., Fair, W. R., & Heston, W. D. W. (1994) · PubMed · Cited by 601
Cited by
Erho, N., Crisan, A., Vergara, I. A., Mitra, A. P., Ghadessi, M., Buerki, C., Bergstralh, E. J., Kollmeyer, T., Fink, S., Haddad, Z., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066855 · Cited by 644
Kratochwil, C., Giesel, F. L., Stefanova, M., Benešová, M., Bronzel, M., Afshar-Oromieh, A., Mier, W., Eder, M., Kopka, K., & Haberkorn, U. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.171397 · Cited by 636
Narayan, V., Barber-Rotenberg, J. S., Jung, I.-Y., Lacey, S. F., Rech, A. J., Davis, M. M., Hwang, W.-T., Lal, P., Carpenter, E. L., Maude, S. L., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01726-1 · Cited by 533
Weineisen, M., Schottelius, M., Simecek, J., Baum, R. P., Yildiz, A., Beykan, S., Kulkarni, H. R., Lassmann, M., Klette, I., Eiber, M., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.158550 · Cited by 532
Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer
Paschalis, A., Sheehan, B., Riisnaes, R., Rodrigues, D. N., Gurel, B., Bertan, C., Ferreira, A., Lambros, M. B. K., Seed, G., Yuan, W., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.06.030 · Cited by 455
Darshan, M. S., Loftus, M. S., Thadani-Mulero, M., Levy, B. P., Escuin, D., Zhou, X. K., Gjyrezi, A., Chanel-Vos, C., Shen, R., Tagawa, S. T., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1417 · Cited by 432
Chen, Y., Pullambhatla, M., Foss, C. A., Byun, Y., Nimmagadda, S., Senthamizhchelvan, S., Sgouros, G., Mease, R. C., & Pomper, M. G. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1357 · Cited by 388
Mannweiler, S., Amersdorfer, P., Trajanoski, S., Terrett, J. A., King, D., & Mehes, G. (2009) · Pathology & Oncology Research · doi:10.1007/s12253-008-9104-2 · Cited by 384
Prostate Cancer Genetics: Variation by Race, Ethnicity, and Geography
Rebbeck, T. R. (2017) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2016.08.002 · Cited by 329
Hillier, S. M., Maresca, K. P., Femia, F. J., Marquis, J. C., Foss, C. A., Nguyen, N., Zimmerman, C. N., Barrett, J. A., Eckelman, W. C., Pomper, M. G., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1682 · Cited by 316
Anti-cancer activity of curcumin loaded nanoparticles in prostate cancer
Yallapu, M. M., Khan, S., Maher, D. M., Ebeling, M. C., Sundram, V., Chauhan, N., Ganju, A., Balakrishna, S., Gupta, B. K., Zafar, N., et al. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.06.040 · Cited by 290
Minner, S., Wittmer, C., Graefen, M., Salomon, G., Steuber, T., Haese, A., Huland, H., Bokemeyer, C., Yekebas, E., Dierlamm, J., et al. (2011) · The Prostate · doi:10.1002/pros.21241 · Cited by 284
Cho, S. Y., Gage, K. L., Mease, R. C., Senthamizhchelvan, S., Holt, D. P., Jeffrey-Kwanisai, A., Endres, C. J., Dannals, R. F., Sgouros, G., Lodge, M., et al. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.104661 · Cited by 279
Targeting signaling pathways in prostate cancer: mechanisms and clinical trials
He, Y., Xu, W., Xiao, Y.-T., Huang, H., Gu, D., & Ren, S. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01042-7 · Cited by 261
Rowe, S. P., Macura, K. J., Mena, E., Blackford, A. L., Nadal, R., Antonarakis, E. S., Eisenberger, M., Carducci, M., Fan, H., Dannals, R. F., et al. (2016) · Molecular Imaging and Biology · doi:10.1007/s11307-016-0957-6 · Cited by 258
Okamoto, S., Thieme, A., Allmann, J., D’Alessandria, C., Maurer, T., Retz, M., Tauber, R., Heck, M. M., Wester, H.-J., Tamaki, N., et al. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.178483 · Cited by 213
“Its expression correlates with the malignancy of the disease, being further increased in mCRPC (4).”
BackgroundKabasakal, L., AbuQbeitah, M., Aygün, A., Yeyin, N., Ocak, M., Demirci, E., & Toklu, T. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3125-3 · Cited by 208
Hupe, M. C., Philippi, C., Roth, D., Kümpers, C., Ribbat-Idel, J., Becker, F., Joerg, V., Duensing, S., Lubczyk, V. H., Kirfel, J., et al. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00623 · Cited by 175
Self-citationPeters, S. M. B., Privé, B. M., de Bakker, M., de Lange, F., Jentzen, W., Eek, A., Muselaers, C. H. J., Mehra, N., Witjes, J. A., Gotthardt, M., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05471-4 · Cited by 88
Petrylak, D. P., Kantoff, P., Vogelzang, N. J., Mega, A., Fleming, M. T., Stephenson, J. J., Frank, R., Shore, N. D., Dreicer, R., McClay, E. F., et al. (2019) · The Prostate · doi:10.1002/pros.23765 · Cited by 84
Lindström, E., Velikyan, I., Regula, N., Alhuseinalkhudhur, A., Sundin, A., Sörensen, J., & Lubberink, M. (2019) · Theranostics · doi:10.7150/thno.31970 · Cited by 32
Kaittanis, C., Bolaender, A., Yoo, B., Shah, N., Ouerfelli, O., & Grimm, J. (2017) · Nano Letters · doi:10.1021/acs.nanolett.7b04209 · Cited by 19
Erdogan, M., Sengul, S. S., Cetin, B., Avcı, M., Yagci, S., Ozkoç, I., Barikan, D. E., & Yildiz, M. (2022) · Annals of Nuclear Medicine · doi:10.1007/s12149-022-01739-3 · Cited by 14
Jansen, B. H. E., Jansen, R. W., Wondergem, M., Srbljin, S., de Klerk, J. M. H., Lissenberg-Witte, B. I., Vis, A. N., van Moorselaar, R. J. A., Boellaard, R., Hoekstra, O. S., et al. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.222513 · Cited by 12
“PSMA is a class II transmembrane glycoprotein that provides a valuable target for radiolabeled imaging, as it is significantly overexpressed in malignant prostate cells (3).”
BackgroundKhatri, W., Chung, H. W., Werner, R. A., Leal, J. P., Pienta, K. J., Lodge, M. A., Gorin, M. A., Pomper, M. G., & Rowe, S. P. (2021) · Diagnostics · doi:10.3390/diagnostics11040665 · Cited by 10
Metadata
- Authors
- Perner, S., Hofer, M. D., Kim, R., Shah, R. B., Li, H., Möller, P., Hautmann, R. E., Gschwend, J. E., Kuefer, R., & Rubin, M. A.
- Venue
- Human Pathology
- Publisher
- Elsevier BV
- Published
- 2007-05
- Volume
- 38
- Issue
- 5
- Pages
- 696-701
- ISSN
- 0046-8177 (ISSN-L)
- OpenAlex
- W2123985787
- Cited by
- 455
- References
- 24
- FWCI
- 7.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.